Samuel Hume

Co-founder of Stematic Labs, where he works on AI tools for systematic reviews and evidence synthesis in biomedical research. Hume is a medical doctor and scientist with oncology and cancer-biology research experience, and has written publicly about AI’s impact on drug discovery and medicine.

Tech’s Hard Problems Are Moving From Demos to Deployment

TBPN’s Jordi Hays and John Coogan use Apple’s WWDC, the jobs report, venture-capital disputes, and interviews with operators in satellites, biotech, fusion, robotics and nuclear power to frame a recurring divide between demonstration and deployment. Their argument is that AI features, reactors, robots, medicines and market stories are now being judged less by whether they can be shown than by whether they can be operated at scale, with infrastructure, regulation, capital and user trust doing much of the hard work.

TBPNJun 8, 202630 min read